Key Takeaways
- Strong top line, margin squeeze: Revenue grew 27.4% YoY on broad-based demand, but PAT dipped slightly as a 3x spike in rice husk costs and other input inflation compressed net margins.
- Capacity build-out is accelerating: Pretilachlor backward integration went live, two more Sandila blocks are due by January 2023, and the Hamirpur greenfield site broke ground, setting up a multi-year growth runway.
- New products are contributing but still ramping: Six new molecules delivered 10% of Q1 revenue (₹22 crore); management expects them to contribute at least ₹100 crore by FY23 year-end as plants stabilize.
- Demand signals remain unequivocally positive: No customer has asked to reduce supplies; on the contrary, requests to increase capacity are coming in, and the order book covers the next 5–6 months.
- What to watch next quarter: Whether the two remaining IPO-promised molecules launch on schedule, the pace of margin recovery as rice husk and carbon disulphide prices stabilize, and any update on Hamirpur’s environmental clearance timeline.
Demand & Order Book
- Export engine firing: Export revenue jumped to ₹101 crore from ₹64 crore a year ago, driven by distinct product offerings and the ability to develop client-specific molecules quickly. Demand from Europe, Australia and other markets was described as "very good robust."
- No recession signals: Management stated explicitly that no customer globally has requested reduced supplies; instead, customers are asking the company to increase capacity and supplies.
- Order visibility: The order book is "very good" and covers the next 5–6 months. A customer for Pretilachlor has provided a one-year forecast, with a firm order expected once they finalize.
- Australia herbicide recovery: A previously flagged inventory overhang in Australia has resolved; the product is now receiving continuous orders and contributed ~15% of total Q1 revenue.
- Old products finding new demand: Captan and Folpet are seeing increased demand as some fungicides get banned in Europe, creating alternative demand for these molecules. Volume is expected to increase slowly in coming years.
- Prosulfocarb stabilizes: After an overstocking issue last year, demand has normalized and the business is expected to be constant going forward. One competitor has entered in a very small way but has not affected the marketing setup.
D. K. Jain: "No, sir, we are not getting any such requests from any of our customers across the world. On the other hand, we are getting requests from the customers to increase the capacity, increased requirements are there, we have not received from any customer, any request for reducing the supplies."
Margin Dynamics & Cost Headwinds
- The rice husk shock: Rice husk prices nearly tripled YoY as coal and gas shortages drove industry-wide fuel switching, adding an incremental cost of ~₹4.5 crore for the quarter. Unit power cost did not increase; the total power cost rise was volume-driven.
- Other expenses surge: Other expenses rose 47% YoY, driven by the 21% volume growth increasing variable costs proportionately, the fuel cost spike, higher contractual labour and processing charges from increased production, and minor freight increases.
- Gross margin holding at ~50%: Commodity prices have slightly declined but not enough to allow price increases. Management expects gross margin and EBITDA margin to remain in the 50% and 26–27% range respectively going forward.
- Carbon disulphide pressure: Prices have risen very severely over the last year, almost 2.5x, and are now beginning to stabilize.
- New molecule margin uncertainty: Management acknowledged that adding new molecules introduces some uncertainty around margins, but the raw material cost filter (45–55% of revenue) is designed to keep outcomes within the target range.
D.K. Jain: "Now, because we are adding few more new molecules, the new molecules, there is some certain degree of uncertainty would be there, isn't it? So, we try to get to as much as possible, but we feel that at least we should be able to maintain this range."
Capacity Expansion: Sandila & Hamirpur
- Pretilachlor backward integration live: The first phase (2,000 tons per annum) was commissioned at Sandila during Q1, using an in-house process developed by R&D and project engineering. A second phase is planned to start later this year.
- Two more Sandila blocks coming: An additional 4,000 metric tons of capacity (two blocks) will be added at Sandila for herbicide technicals and intermediates. One block is expected to commission by September 2022, the other by January 2023. With this, the Sandila site will be fully occupied.
- Hamirpur greenfield breaks ground: The ground-breaking ceremony was performed by the Prime Minister. The site will operate as a 100% subsidiary, Shalvis Specialities Limited. The EIA report is under completion and expected to be submitted by August end, with environmental clearance anticipated by October/November 2022.
- Hamirpur revenue timeline: Management expects some revenue from the new site in FY24 third to fourth quarter, approximately one year from receiving clearance. Capex is projected at ₹100–125 crore per year for the coming 3–4 years.
- New land near Kanpur: A 25-acre parcel has been purchased; statutory clearances have been applied for and work will start once environmental clearance is received.
- Semi-commercial pilot plant: A small multi-purpose plant is under construction for niche products requiring very small volumes. Management prefers dedicated plants over multipurpose ones due to contamination risks.
New Product Pipeline & R&D
- Six of eight IPO molecules launched: Five technicals and one intermediate have been launched so far, including one intermediate that was previously largely imported and is now manufactured in India. The remaining two molecules are expected during the rest of FY23.
- Revenue contribution ramping: The six new molecules contributed ₹22 crore (10% of Q1 sales) and are still stabilizing. Management expects them to contribute at least ₹100 crore by FY23 year-end, with a larger contribution next year.
- Asset turnover math: Peak sales from new products are expected at ~2.5x asset turnover on capex. With ~₹70 crore spent last year and ~₹70 crore planned this year, existing facilities can generate revenues of almost ₹1,000 crore by FY24.
- R&D team strengthened: Two very senior scientists of national repute have been added. Yield improvement remains an ongoing focus as production scales up and plants stabilize.
- Product selection discipline: The raw material cost filter is strict: raw material cost should not exceed 50% of revenue (range 45–55%). Products falling outside this range are rejected. Products for the Hamirpur site have already been shortlisted using this criterion.
D. K. Jain: "Though we try to make as much as possible our normal criteria is that the raw material should not be more than 50% and until now we have been able to maintain that... if we don't find the product to be in that range and it is very much out from that point, then we don't take up that product at all..."
Balance Sheet & Working Capital
- Net cash position improved: Net cash rose to ₹105 crore from ₹93 crore in March, reflecting strong cash generation.
- Working capital stable: The net working capital cycle was unchanged versus March 2022. Receivables improved by 15 days, but this was offset by an inventory increase of 10–11 days and a reduction in creditors of 5 days.
- Monsoon impact contained: The delayed monsoon had no material impact on Q1 because formulations are only 22% of turnover. Some inventory build-up occurred but was not significant.
- Capacity utilization improved: Utilization rose to ~80% in Q1 from ~65% in Q4 FY22, reflecting the demand recovery and production ramp-up.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20–25% annual growth rate | Coming 3–5 years |
| EBITDA margin | Maintain 26–27% range, with one or two points variation possible | Ongoing |
| Sandila Block 1 commissioning | New manufacturing block (part of 4,000 MT addition) | September 2022 |
| Sandila Block 2 commissioning | Second new manufacturing block | January 2023 |
| Remaining IPO molecules | Two more molecules to be launched | During remaining part of FY23 |
| New product revenue contribution | At least ₹100 crore from new molecules | By FY23 year-end |
| Hamirpur environmental clearance | EIA report submission by August end; clearance expected | October/November 2022 |
| Hamirpur first revenue | Some revenue from the new site | FY24 third to fourth quarter |
| Hamirpur annual capex | ₹100–125 crore per year | Coming 3–4 years |
| FY24 revenue from existing facilities | Almost ₹1,000 crore at 2.5x asset turnover on ~₹140 crore total capex | FY24 |
| Pretilachlor Phase 2 | Work to commence on second phase of backward integration | Later part of current fiscal year |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Total revenue | ₹221 crore, +27.4% YoY |
| EBITDA | ₹59 crore |
| EBITDA margin | 26.6% |
| PAT | ₹41 crore, vs ₹42 crore in Q1 FY22 |
| PAT margin | 18.5% |
| Export revenue | ₹101 crore, vs ₹64 crore in Q1 FY22 |
| Domestic revenue | ₹118 crore, vs ₹106 crore in Q1 FY22 |
| Technical revenue | ₹170 crore |
| Formulation revenue | ₹48 crore |
| Revenue growth target | 20-25% annually, for the coming 3-5 years |
| EBITDA margin guidance | 26-27% |
| Volume growth | 21% YoY |
| Capacity utilization | ~80%, vs ~65% in Q4 FY22 |
| Installed technical capacity | 23,500 metric tons, up from 19,500 metric tons last year |
| New products revenue contribution | ~₹22 crore, 10% of total revenue |
| New molecules launched in Q1 | 6 |
| Net cash | ~₹105 crore, as of June 30 (debt ~₹20 crore, FD and bank balance ~₹125 crore) |
| Capex incurred in Q1 | ₹17 crore |
| FY23 planned capex (Sandila) | ₹70 crore |
| FY23 planned capex (Hamirpur) | ~₹20 crore |
| Gross margin | ~50% |
| Formulation share of total turnover | 22% |
| Energy cost increase impact | ~₹4.5 crore incremental in Q1, rice husk prices up ~200% YoY |
| Herbicide product (Australia) revenue share | ~15% of total revenue in Q1 |
| Expected new products contribution by FY23 year-end | At least ₹100 crore |